Noninvasive assessment of cancer response to therapy

被引：59

作者：

Han, Zhaozhong ^{[1
]}

Fu, Allie ^{[1
]}

Wang, Hailun ^{[1
,2
]}

Diaz, Roberto ^{[1
]}

Geng, Ling ^{[1
]}

Onishko, Halina ^{[1
]}

Hallahan, Dennis E. ^{[1
,2
,3
,4
]}

机构：

[1] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Sch Med, Dept Biomed Engn, Nashville, TN 37232 USA

[4] Vanderbilt Ingram Can Ctr, Nashville, TN 37232 USA

来源：

NATURE MEDICINE | 2008年 / 14卷 / 03期

关键词：

D O I：

10.1038/nm1691

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration

引用

页码：343 / 349

页数：7

共 26 条

[1] Steps toward mapping the human vasculature by phage display [J].

Arap, W ;

Kolonin, MG ;

Trepel, M ;

Lahdenranta, J ;

Cardó-Vila, M ;

Giordano, RJ ;

Mintz, PJ ;

Ardelt, PU ;

Yao, VJ ;

Vidal, CI ;

Chen, L ;

Flamm, A ;

Valtanen, H ;

Weavind, LM ;

Hicks, ME ;

Pollock, RE ;

Botz, GH ;

Bucana, CD ;

Koivunen, E ;

Cahill, D ;

Troncoso, P ;

Baggerly, KA ;

Pentz, RD ;

Do, KA ;

Logothetis, CJ ;

Pasqualini, R .

NATURE MEDICINE, 2002, 8 (02) :121-127

[2]

Belhocine T, 2002, CLIN CANCER RES, V8, P2766

[3]

Drevs J, 2002, CANCER RES, V62, P4015

[4] Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels [J].

Hallahan, D ;

Geng, L ;

Qu, SM ;

Scarfone, C ;

Giorgio, T ;

Donnelly, E ;

Gao, X ;

Clanton, J .

CANCER CELL, 2003, 3 (01) :63-74

[5]

HALLAHAN DE, NAT PROTOC

[6] Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-displayed CV-N mutant library [J].

Han, ZZ ;

Xiong, CY ;

Mori, T ;

Boyd, MR .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 292 (04) :1036-1043

[7] PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy [J].

Hess-Stumpp, H ;

Haberey, M ;

Thierauch, KH .

CHEMBIOCHEM, 2005, 6 (03) :550-557

[8] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J].

Kabbinavar, F ;

Hurwitz, HI ;

Fehrenbacher, L ;

Meropol, NJ ;

Novotny, WF ;

Lieberman, G ;

Griffing, S ;

Bergsland, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :60-65

[9]

Ladner RC, 1999, Q J NUCL MED, V43, P119

[10]

Mendel DB, 2003, CLIN CANCER RES, V9, P327

← 1 2 3 →